Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review.

Paxlovid (nirmatrelvir/ritonavir) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/41634606

Ashley S Cha-Silva; Cynthia L Gong; David Campbell; David L Veenstra; Kristen Migliaccio-Walle; Mary M Moran; Mendwas Dzingina; Romina Quercia; Tendai Mugwagwa; Tobias Bergroth

Feb 4, 2026